These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro evaluation of potential hepatotoxicity induced by drugs. Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064 [TBL] [Abstract][Full Text] [Related]
3. Effects of liver disease on pharmacokinetics. An update. Rodighiero V Clin Pharmacokinet; 1999 Nov; 37(5):399-431. PubMed ID: 10589374 [TBL] [Abstract][Full Text] [Related]
4. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Buratti S; Lavine JE Curr Opin Pediatr; 2002 Oct; 14(5):601-7. PubMed ID: 12352255 [TBL] [Abstract][Full Text] [Related]
5. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Lewis JH Expert Opin Drug Saf; 2002 Jul; 1(2):159-72. PubMed ID: 12904150 [TBL] [Abstract][Full Text] [Related]
6. A clinical pharmacologist's view of drug hepatotoxicity. Dujovne CA Pharmacol Res Commun; 1977 Jan; 9(1):1-15. PubMed ID: 325578 [No Abstract] [Full Text] [Related]
7. [Dangerous drugs in hepatic insufficiency]. Isal JP; Caulin C Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025 [No Abstract] [Full Text] [Related]
8. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages. Giri S; Nieber K; Bader A Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107 [TBL] [Abstract][Full Text] [Related]
9. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298 [TBL] [Abstract][Full Text] [Related]
12. The role of metabolic activation in drug-induced hepatotoxicity. Park BK; Kitteringham NR; Maggs JL; Pirmohamed M; Williams DP Annu Rev Pharmacol Toxicol; 2005; 45():177-202. PubMed ID: 15822174 [TBL] [Abstract][Full Text] [Related]
13. Hepatic disease and drug pharmacokinetics. Williams RL; Mamelok RD Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418 [TBL] [Abstract][Full Text] [Related]
14. The spectrum of hepatotoxicity due to drugs. Sherlock S Lancet; 1986 Aug; 2(8504):440-4. PubMed ID: 2874423 [TBL] [Abstract][Full Text] [Related]
15. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs]. Pessayre D; Benhamou JP C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767 [TBL] [Abstract][Full Text] [Related]
16. [Hepatotoxic effects of drugs in childhood (author's transl)]. Morlán A; Jara P An Esp Pediatr; 1982 Jan; 16(1):66-76. PubMed ID: 7081853 [TBL] [Abstract][Full Text] [Related]
17. Alcohol effects on drug-nutrient interactions. Seitz HK Drug Nutr Interact; 1985; 4(1-2):143-63. PubMed ID: 3908040 [TBL] [Abstract][Full Text] [Related]
18. Are chemically reactive metabolites responsible for adverse reactions to drugs? Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355 [TBL] [Abstract][Full Text] [Related]
19. Protein binding and kinetics of drugs in liver diseases. Blaschke TF Clin Pharmacokinet; 1977; 2(1):32-44. PubMed ID: 322909 [TBL] [Abstract][Full Text] [Related]